INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30801, 28984, 'Vardenafil', 'Liver Diseases', 'Vardenafil is cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of this agent has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild hepatic impairment, however, therapy with this agent should not be administered to patients with moderate to severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of the oral tablet might be used as initial therapy and the maximum dose should not exceed 10 mg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30802, 28985, 'Vardenafil', 'Liver Diseases', 'Vardenafil is cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of this agent has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild hepatic impairment, however, therapy with this agent should not be administered to patients with moderate to severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of the oral tablet might be used as initial therapy and the maximum dose should not exceed 10 mg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30803, 28986, 'Vardenafil', 'Liver Diseases', 'Vardenafil is cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of this agent has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild hepatic impairment, however, therapy with this agent should not be administered to patients with moderate to severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of the oral tablet might be used as initial therapy and the maximum dose should not exceed 10 mg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30804, 28987, 'Vardenafil', 'Liver Diseases', 'Vardenafil is cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of this agent has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild hepatic impairment, however, therapy with this agent should not be administered to patients with moderate to severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of the oral tablet might be used as initial therapy and the maximum dose should not exceed 10 mg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30805, 28988, 'Vardenafil', 'Liver Diseases', 'Vardenafil is cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of this agent has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild hepatic impairment, however, therapy with this agent should not be administered to patients with moderate to severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of the oral tablet might be used as initial therapy and the maximum dose should not exceed 10 mg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30806, 28989, 'Vardenafil', 'Liver Diseases', 'Vardenafil is cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of this agent has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild hepatic impairment, however, therapy with this agent should not be administered to patients with moderate to severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of the oral tablet might be used as initial therapy and the maximum dose should not exceed 10 mg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30807, 28990, 'Vardenafil', 'Liver Diseases', 'Vardenafil is cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of this agent has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild hepatic impairment, however, therapy with this agent should not be administered to patients with moderate to severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of the oral tablet might be used as initial therapy and the maximum dose should not exceed 10 mg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30808, 28992, 'Vardenafil', 'Liver Diseases', 'Vardenafil is cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of this agent has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild hepatic impairment, however, therapy with this agent should not be administered to patients with moderate to severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of the oral tablet might be used as initial therapy and the maximum dose should not exceed 10 mg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30809, 28995, 'Vardenafil', 'Liver Diseases', 'Vardenafil is cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of this agent has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild hepatic impairment, however, therapy with this agent should not be administered to patients with moderate to severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of the oral tablet might be used as initial therapy and the maximum dose should not exceed 10 mg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30810, 29005, 'Vardenafil', 'Liver Diseases', 'Vardenafil is cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of this agent has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild hepatic impairment, however, therapy with this agent should not be administered to patients with moderate to severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of the oral tablet might be used as initial therapy and the maximum dose should not exceed 10 mg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30811, 29006, 'Vardenafil', 'Liver Diseases', 'Vardenafil is cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of this agent has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild hepatic impairment, however, therapy with this agent should not be administered to patients with moderate to severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of the oral tablet might be used as initial therapy and the maximum dose should not exceed 10 mg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30812, 29007, 'Vardenafil', 'Liver Diseases', 'Vardenafil is cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of this agent has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild hepatic impairment, however, therapy with this agent should not be administered to patients with moderate to severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of the oral tablet might be used as initial therapy and the maximum dose should not exceed 10 mg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30813, 29144, 'Vardenafil', 'Liver Diseases', 'Vardenafil is cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of this agent has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild hepatic impairment, however, therapy with this agent should not be administered to patients with moderate to severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of the oral tablet might be used as initial therapy and the maximum dose should not exceed 10 mg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30814, 29296, 'Vardenafil', 'Liver Diseases', 'Vardenafil is cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of this agent has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild hepatic impairment, however, therapy with this agent should not be administered to patients with moderate to severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of the oral tablet might be used as initial therapy and the maximum dose should not exceed 10 mg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30815, 31180, 'Vardenafil', 'Liver Diseases', 'Vardenafil is cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of this agent has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild hepatic impairment, however, therapy with this agent should not be administered to patients with moderate to severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of the oral tablet might be used as initial therapy and the maximum dose should not exceed 10 mg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30816, 32236, 'Vardenafil', 'Liver Diseases', 'Vardenafil is cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of this agent has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild hepatic impairment, however, therapy with this agent should not be administered to patients with moderate to severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of the oral tablet might be used as initial therapy and the maximum dose should not exceed 10 mg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30817, 33836, 'Vardenafil', 'Liver Diseases', 'Vardenafil is cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of this agent has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild hepatic impairment, however, therapy with this agent should not be administered to patients with moderate to severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of the oral tablet might be used as initial therapy and the maximum dose should not exceed 10 mg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30818, 33837, 'Vardenafil', 'Liver Diseases', 'Vardenafil is cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of this agent has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild hepatic impairment, however, therapy with this agent should not be administered to patients with moderate to severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of the oral tablet might be used as initial therapy and the maximum dose should not exceed 10 mg.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30819, 7255, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30820, 7519, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30821, 10684, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30822, 18514, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30823, 25111, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30824, 25112, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30825, 25113, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30826, 25114, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30827, 25115, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30828, 25778, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30829, 26260, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30830, 26261, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30831, 26353, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30832, 28605, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30833, 28981, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30834, 28982, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30835, 28983, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30836, 28984, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30837, 28985, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30838, 28986, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30839, 28987, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30840, 28988, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30841, 28989, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30842, 28990, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30843, 28992, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30844, 28995, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30845, 29005, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30846, 29006, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30847, 29007, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30848, 29144, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30849, 29296, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30850, 31180, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30851, 32236, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30852, 33836, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30853, 33837, 'Vardenafil', 'Phenylketonurias', 'Vardenafil oral disintegrating tablet contains 1.01 mg phenylalanine per tablet.  The phenylalanine content should be considered when this product is used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30854, 0, 'Vasopressin', 'Nephritis', 'Chronic nephritis with nitrogen retention contraindicates the use of vasopressin until reasonable nitrogen blood levels have been attained.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30855, 0, 'Vasopressin', 'Kidney Diseases', 'Vasopressin is contraindicated in patients with chronic nephritis with nitrogen retention.  This until reasonable nitrogen blood levels have been attained.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30856, 0, 'Vasopressin', 'Vascular Diseases', 'Vasopressin should not be used in patients with vascular disease, especially disease of the coronary arteries, except with extreme caution.  In such patients, even small doses may precipitate anginal pain, and large doses may cause myocardial infarction.  If a decision is made to use the drug, ECG monitoring should be performed periodically during therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30857, 0, 'Vasopressin', 'Water Intoxication', 'Water intoxication and hyponatremia may occur during therapy with vasopressin or desmopressin due to their antidiuretic action.  Patients are most likely to experience this problem if their fluid intake is excessive or if they do not require antidiuresis, such as when they are administered these agents for their hemostatic effects.  Fluid intake should be adjusted carefully to avoid overhydration, particularly in children, elderly, and patients with conditions that may be exacerbated by fluid retention, including epilepsy, migraine, asthma, and heart failure.  Patients should be monitored for signs of water intoxication (e.g., listlessness, drowsiness, and headaches), which may rarely progress to seizures and coma.  The use of desmopressin is contraindicated in patients with hyponatremia or a history of hyponatremia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30858, 0, 'Vibegron', 'Urinary Retention', 'Vibegron may increase the risk of urinary retention, particularly in patients with bladder outlet obstruction and in those taking muscarinic antagonist medications to treat overactive bladder (OAB).  It is recommended to monitor for signs and symptoms of urinary retention and discontinue the use of vibegron if a patient develops urinary retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30859, 4005, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30860, 4006, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30861, 4010, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30862, 6386, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30863, 12174, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30864, 17234, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30865, 17235, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30866, 17236, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30867, 18100, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30868, 18106, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30869, 19873, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30870, 19874, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30871, 19875, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30872, 20709, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30873, 20711, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30874, 20712, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30875, 21072, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30876, 29096, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30877, 29097, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30878, 29098, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30879, 29099, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30880, 29103, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30881, 29110, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30882, 29111, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30883, 29212, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30884, 29213, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30885, 29214, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30886, 30447, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30887, 31559, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30888, 32779, 'Venlafaxine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30889, 4005, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30890, 4006, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30891, 4010, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30892, 6386, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30893, 12174, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30894, 17234, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30895, 17235, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30896, 17236, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30897, 18100, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30898, 18106, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30899, 19873, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30900, 19874, 'Venlafaxine', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '', 'DDInter', 0);
